Krka (company)

KRKA, d. d., Novo mesto

Type	Public
Industry	Pharmaceutical
Founded	1954
Headquarters	Šmarješka cesta 6, 8501 Novo Mesto, Slovenia
Key people	Jože Colarič, President of the Management Board and Chief Executive
Products	Prescription pharmaceuticals, non-prescription products, animal health products, health-resort and tourist services
Number of employees	10,564 (31 December 2015)
Website	krka.biz

Krka, d. d., Novo mesto is an international generic pharmaceutical company with headquarters in Novo Mesto, Slovenia. In 2015, Krka Group’s total sales amounted to EUR 1,164.6 million. Over the previous five years, average annual sales growth had been 2.9 %. Krka’s was selling products to more than 70 countries. As well as a number of companies and representative offices abroad, Krka also had production and distribution centres in the Russian Federation, Poland, Croatia and Germany. At the end of March 2015, Krka employed 10,564.

Krka’s business is founded on pharmaceutical and chemical activities. Prescription pharmaceuticals remain its main product group, with an 83.4 % share of Krka Group’s total sales. They are followed in sales volume by non-prescription products (9.2 %) and animal health products (4.5 %). Its Terme Krka spas, hotels and tourism subsidiary contributed 2.7 % of the parent group's sales volume.

The most important of Krka’s therapeutic groups include treatments for: cardiovascular diseases, alimentary tract diseases and metabolic disorders, and central nervous system diseases. They are followed by the medicines for the systemic treatment of infections, the medicines for the treatment of diseases of the blood and blood-forming organs, and the medicines for urinary tract diseases as well as the medicines for respiratory system diseases.

Its portfolio of treatments for cardiovascular disease include ACE inhibitors to treat high blood pressure (including enalapril and perindopril), sartans for those unable to tolerate ACE inhibitors (including losartan, valsartan and telmisartan), statins to reduce high cholesterol levels (including simvastatin, atorvastatin and rosuvastatin) and clopidogrel, a blood clot inhibitor.